NASDAQ · Finance

Oaktree Acquisition Corp. III Life Sciences (OACC)

At June 30, 2026 it held $1.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.

Price

$10.78

-0.19% on the day · September 25, 2026

52-week range $10.45 to $10.88

What Oaktree Acquisition Corp. III Life Sciences does

Oaktree Acquisition Corp. III Life Sciences is registered with the SEC under industry code SIC 6770 (Blank Checks). Its shares trade on NASDAQ under the ticker OACC.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	-$1.2M	$7.3M	n/a	n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around November 12, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 13, 2025. Not a date the company has announced. See the report calendar

Latest SEC filings

What Oaktree Acquisition Corp. III Life Sciences has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 21, 2026
Preliminary proxy statement PRE 14A
August 14, 2026
Passive stake (5% or more) SCHEDULE 13G
August 13, 2026
Passive stake (5% or more) SCHEDULE 13G
August 12, 2026
Quarterly report 10-Q · period to June 30, 2026Net income fell 14% to $1.6M.
May 15, 2026
Passive stake (5% or more) SCHEDULE 13G
May 13, 2026
Quarterly report 10-Q · period to March 31, 2026Net income fell 16% to $1.4M.
May 11, 2026
Passive stake (5% or more) SCHEDULE 13G
March 26, 2026
Annual report 10-K · period to December 31, 2025Net income was $7.3M.
February 11, 2026
Passive stake changed SCHEDULE 13G/A
November 13, 2025
Quarterly report 10-Q · period to September 30, 2025Net income of $2M versus a net loss of $48.1K.

Recent insider filings (Forms 3, 4 and 144): 9, the latest on October 29, 2025. Insider transactions on SEC

Who owns OACC

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
Barclays PLC13G, passive	6.99%	1,384,810	August 13, 2026
Decagon Asset Management LLP13G, passive with 1 related filers	5.52%	1,091,327	August 14, 2026
Fort Baker Capital Management LP13G, passive with 2 related filers	5.1%	1,000,000	May 15, 2026

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about OACC

What does Oaktree Acquisition Corp. III Life Sciences do?

Oaktree Acquisition Corp. III Life Sciences is registered with the SEC under industry code SIC 6770 (Blank Checks). Its shares trade on NASDAQ under the ticker OACC.

Is Oaktree Acquisition Corp. III Life Sciences profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $6.8M.

When did Oaktree Acquisition Corp. III Life Sciences last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the preliminary proxy statement from September 21, 2026.

Similar companies

IPCX

Inflection Point Acquisition Corp. III

AVNI

Arvana Inc

MTAL

Metals Acquisition Corp. II

HCMA

Hcm III Acquisition Corp.

TACO

Berto Acquisition Corp.

CUB

Lionheart Holdings

Compare OACC with

Compare OACC with any company

Follow OACC

Get an email when Oaktree Acquisition Corp. III Life Sciences files with the SEC: results, executive changes, material agreements and annual reports.

Follow OACC: get an email when it files

Where the numbers come from

Financial figures are the values Oaktree Acquisition Corp. III Life Sciences tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.